SCHEMBL309222

SCHEMBL309222

O=S(=O)(O)c1cccc(-c2cccc(Cl)c2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
TSHR P16473 2/20 0.52
HSD17B10 Q99714 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
KAT6A Q92794 1/20 0.50
ALOX5 P09917 1/20 0.50
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
PGR P06401 2/20 0.46
ESR2 Q92731 1/20 0.46
FLT1 P17948 1/20 0.46
FLT4 P35916 1/20 0.46
KDR P35968 1/20 0.46
ACLY P53396 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
MMP2 P08253 2/20 0.43
MMP1 P03956 1/20 0.43
MMP3 P08254 1/20 0.43
MMP7 P09237 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL975190 0.89 TSHR (0.61) ALDH1A1TSHRHSD17B10TDP1SMN1; SMN2
SCHEMBL308569 0.89 KAT6A (0.50) ALDH1A1TSHRHSD17B10TDP1KAT6A
SCHEMBL29960292 0.87 ALDH1A1 (0.59) ALDH1A1TSHRHSD17B10TDP1MEN1
SCHEMBL5081851 0.87 TSHR (0.59) ALDH1A1TSHRHSD17B10TDP1SMN1; SMN2
SCHEMBL27903792 0.87 TSHR (0.59) ALDH1A1TSHRHSD17B10TDP1KAT6A
SCHEMBL15509798 0.87 TSHR (0.59) ALDH1A1TSHRHSD17B10TDP1SMN1; SMN2
SCHEMBL294451 0.87 ALDH1A1 (0.59) ALDH1A1TSHRHSD17B10TDP1MEN1
SCHEMBL8477676 0.87 ALDH1A1 (0.59) ALDH1A1TSHRHSD17B10TDP1MEN1
SCHEMBL1416443 0.87 TSHR (0.59) ALDH1A1TSHRHSD17B10TDP1SMN1; SMN2
SCHEMBL307761 0.86 ALOX5 (0.53) TSHRKAT6AALOX5SMN1; SMN2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093245-B2 Anticancer agents; potent Deoxycytidine kinase inhibitors; inhibit thymidine kinase; inhibit uridine kinase; N-[3-(4-amino-5-fluoro-2-oxo-2H-pyrimidin-1-yl)-cyclopentyl]-3-bromo-benzenesulfonamide LEXICON PHARMACEUTICALS, INC. (US) 2012-01-10 US disclosed
US-20080182847-A1 4-AMINO-1H-PYRIMIDIN-2-ONE BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE OXFORD FINANCE LLC, AS COLLATERAL AGENT 2008-07-31 US disclosed
EP-0395883-B1 Mixtures of poly(arylene sulfides) with sulfonic end groups or their derivates with poly(arylene sulfides, and their use BAYER AG (DE) 1995-05-03 EP disclosed
US-5068312-A Molding materials formed by reacting dihalogen compounds with a sulfur donor in a solvent BAYER AKTIENGESELLSCHAFT (DE) 1991-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182847-A1 4-AMINO-1H-PYRIMIDIN-2-ONE BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE TPMT, DHFR, GLS2 ALDH1A1 200/4885TSHR 3802/4885HSD17B10 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.